SGLT-2 inhibitors have shown efficacy beyond their preventive function, exhibiting positive effects in decelerating kidney disease progression and reducing cardiovascular events in individuals with pre-existing kidney disease and diabetes [29]. In addition, a comprehensive treatment plan may include prescribing medications such as statins and erythropoiesis-stimulating agents to manage dyslipidemia and anemia, respectively [30]. This evidence concerns the gene SLC5A2 and diabetes mellitus.